Bitwise has filed for an AI drug discovery ETF, expanding its lineup of thematic crypto and technology investment products. The proposed fund would target companies involved in leveraging artificial intelligence for pharmaceutical research and development. The filing marks another step in the growing intersection between AI-driven biotech innovation and regulated investment vehicles available to digital-asset-focused asset managers.